Insights

Panelists discuss the treatment of relapsed and refractory multiple myeloma, as well as sequencing strategies aimed at optimizing patient care and minimizing treatment-related side effects,presenting two real-world patient cases and explain our treatment approach, highlighting how they incorporate recent data into our practice.

Kelly E. McCann, MD, PhD; and Gregory Vidal, MD, PhD, discuss how triple-positive breast cancer (hormone receptor positive and HER2 positive) requires specialized treatment approaches, including standard taxane with pertuzumab-trastuzumab combinations, the integration of CDK 4/6 inhibitors, considerations for ovarian suppression in premenopausal patients, and sequential therapy options for metastatic disease including antibody-drug conjugates and tyrosine kinase inhibitors.

Panelists discuss how immune-oncology therapies and biomarkers like TMB, MSI, and HER2 are shaping treatment strategies and decision-making in advanced endometrial cancer, highlighting the need for further research and improved sequencing approaches.

Experts discuss the latest clinical data on tyrosine kinase inhibitor (TKI) therapy for gastrointestinal stromal tumors (GIST), focusing on optimizing treatment selection and sequencing strategies for patients progressing beyond first-line therapy, with insights into how molecular characterization and recent clinical trials inform decisions across multiple treatment lines, illustrated through patient case discussions.

Experts explore the growing role of CAR T-cell therapy in the treatment of r/r MM, as well as dive into recent data updates, importance of early referral, and future directions of CAR-T in this rapidly evolving field.

Christine M. Lovly, MD, PhD, FASCO; and Balazs Halmos, MD, MS, discuss how the first-line treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC) is evolving, with osimertinib as the standard, while combinations are explored to enhance efficacy. FLAURA, FLAURA2, and MARIPOSA trials inform treatment selection, balancing efficacy, safety, and CNS activity. Patient factors such as disease burden and resistance guide sequencing decisions, with MARIPOSA-2 and PALOMA-3 shaping second-line choices. Managing adverse events in combination regimens remains key. Unmet needs include overcoming resistance and improving long-term outcomes.

Experts explore the evolving role of chimeric antigen receptor (CAR) T-cell therapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), with a focus on patient selection, recent data updates, and sequencing strategies.

Julia Rotow, MD and Edgardo S. Santos Castillero, MD, FACP, FASCO, discuss how, when selecting frontline therapy for EGFR-mutated non–small cell lung cancer (NSCLC), key considerations include central nervous system involvement, metastases, and mutational factors like TP53. Shared decision-making prioritizes progression-free survival, toxicity, and convenience. Future therapy sequencing, evolving MARIPOSA data, and novel agents shape treatment strategies while balancing efficacy and tolerability.

Benjamin P. Levy, MD, and Misty D. Shields, MD, PhD, discuss Bridging the Gaps in lung cancer, a collection and review of updated data from the Winter Lung Cancer Conference 2025, that was significant to their practice and future implications of data across 6 key areas, including small cell lung cancer, perioperative treatment strategies in non–small cell lung cancer (NSCLC), advancements in unresectable early-stage NSCLC, treatment strategies for EGFR-mutated NSCLC, targeting ALK/ROS1/HER2/NRG1 mutations in NSCLC, and immunotherapy in advanced NSCLC.

Heather Wakelee, MD, FASCO, and Roy S. Herbst, MD, PhD, discuss how recent clinical trials demonstrate superior outcomes with combination therapies over single-agent osimertinib in EGFR-positive NSCLC, while highlighting the need for careful toxicity management and continued research to address treatment resistance.

Expert discussions on the latest advances in biomarker testing, endocrine resistance, and treatment sequencing with oral SERDs and other emerging therapies to enhance outcomes in HR+/HER2- metastatic breast cancer.